

**OptiBiotix Health plc**  
("OptiBiotix" or the "Company")

**Issue of Options**

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that the Company has issued 358,772 options over new ordinary shares with an exercise price of 11 pence per share ("New Options") to Sofia Kolyda, a Director of the Company.

The New Options expire on 6 August 2035 with 269,079 of the New Options vesting on the first anniversary of the options being granted being 6 August 2026 and the balance (comprising 89,693 New Options) vesting once the Company signs a commercial agreement with a partner providing equal or greater than £100k revenues per annum for products containing SweetBiotix.

The issue of the New Options follows the expiration of 358,772 options of ordinary shares granted to Sofia Kolyda which expired in March 2025 of which 75% had vested.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

**For further information, please contact:**

**OptiBiotix Health plc**  
Neil Davidson, Chairman  
Stephen O'Hara, Chief Executive

[www.optibiotix.com](http://www.optibiotix.com)  
*Contact via Walbrook below*

**Cairn Financial Advisers LLP (NOMAD and Broker)**  
Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: 020 7213 0880

**Walbrook PR Ltd**  
Anna Dunphy

Mob: 07876 741 001

**About OptiBiotix - [www.optibiotix.com](http://www.optibiotix.com)**

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>					
a.	Name	Sofia Kolyda				
<b>2</b>	<b>Reason for notification</b>					
a.	Position/Status	Director				
b.	Initial notification/ Amendment	Initial Notification				
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a.	Name	OptiBiotix Health Plc				
b.	LEI					
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a.	Description of the financial instrument, type of instrument  Identification Code	Options over new ordinary shares of 2p each  ISIN: GB00BP0RTP38				
b.	Nature of the transaction	Issue of options pursuant to the New Options				
c.	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s) per share</td> <td>Volume(s)</td> </tr> <tr> <td>11p</td> <td>358,772</td> </tr> </table>	Price(s) per share	Volume(s)	11p	358,772
Price(s) per share	Volume(s)					
11p	358,772					
d.	Aggregated information - Volume - Price	N/A				
e.	Date of the transaction	6 August 2025				
f.	Place of the transaction	London				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSSDFIIEISEIA